Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AECOPD alpha-1 antitrypsin study
2024-517613-33-00Phase 2Authorised
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Prolastin arm with Placebo arm (2 arms). Primary endpoint: Change in plasma concentration of IL-6 at 7 days after randomization. Planned start Mar 2025; status: authorised.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2024-517613-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517613-33-00.